PMC3836303_01
TC images of vulvar cancer lesion before (a) and after (b) neoadjuvant chemotherapy.
CRIM.OBGYN2013-427141.001.jpg
PMC3836303_01_CRIM.OBGYN2013-427141.001.jpg
fig1
The abdomen-pelvic computed tomography (CT) revealed an enlarged area in the right vulvovaginal wall (Figure 1(a)) and right inguinal enlarged lymph node, measuring 2 cm in the largest diameter. On physical examination, performed after the third cycle of chemotherapy, the vulvar lesion was markedly reduced and this finding was confirmed at abdomen-pelvic CT scan, which showed no evidence of the disease (Figure 1(b)), with regression of inguinal lymphadenopathy.
(a) Ulcerated lesion of the uterine cervix: the bottom of the ulcer shows an adenocarcinomatous proliferation. Haematoxylin-eosin, 100x. (b) Higher magnification of the malignancy, showing a moderately differentiated adenocarcinoma (G2). (c) Immunohistochemical expression of cytokeratin 20 in the neoplastic glands.
CRIM.OBGYN2013-427141.002.jpg
PMC3836303_01_CRIM.OBGYN2013-427141.002.jpg
fig2
At macroscopic histological examination, a vulvar nodule measuring 1.5 cm in diameter was found; microscopically, this lesion presented pathological and immunohistochemical features of vulvar adenocarcinoma of colorectal type (Figures 2(a)-2(b)).